incrementalTreatment update

Bortezomib (proteasome inhibitor) case report published

Schnitzler Syndrome →

Summary

Novel use of bortezomib in a patient without detectable serum IL-1β and absent MYD88 L265P.

Related treatments

BortezomibProteasome inhibitor (NF-κB pathway)
Investigational lineSingle case report

Related genes

MYD88L265P (somatic)
The most significant genetic finding. Same mutation found in >90% of Waldenström's macroglobulinemia. Drives persistent NF-κB activation.

More from Schnitzler Syndrome

incrementalNew research

Weekly research monitor: 4 new sources added (2025-2026)

significantTreatment update

AIDA Network real-world IL-1 inhibitor data: 60-month retention 64.7%

significantNew research

Neutrophils identified as predominant IL-1β source in SchS skin

incrementalGenetic finding

Low-level NLRP3 mosaicism extends Schnitzler phenotypic spectrum

ID: schnitzler-syndrome-update-1Type: treatment_updateImpact: incremental